Status:
COMPLETED
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
Lead Sponsor:
AstraZeneca
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease h...
Eligibility Criteria
Inclusion
- · Life expectancy of at least 8 weeks.
- Histologically or cytologically confirmed non-small cell bronchogenic carcinoma: adenocarcinoma (including bronchoalveolar), squamous cell carcinoma, large cell carcinoma or mixed (adenocarcinoma and squamous) or undifferentiated carcinoma
- Not suitable for chemotherapy
- WHO Performance status 0,1, 2 or 3
Exclusion
- Newly diagnosed CNS mets
- Less than 1 week since completion of prior radiotherapy or persistence of any radiotherapy related toxicity
- ALT/AST greater than 5 x upper limit of normal
- ANC less than 1.0 x 109/L or platelets less than 100 x 109/L
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
1692 Patients enrolled
Trial Details
Trial ID
NCT00242801
Start Date
July 1 2003
End Date
April 1 2005
Last Update
April 23 2009
Active Locations (211)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Capital Federal, Buenos Aires, Argentina
2
Research Site
Bahía Blanca, Argentina
3
Research Site
Buenos Aires, Argentina
4
Research Site
La Plata, Argentina